It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts. Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity. We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms. Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab. Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
Access to glycoenzymes for basic and applied research is limited by difficulties with their recombinant expression. Here, the authors describe a universal strategy for converting membrane-bound glycosyltransferases into water-soluble biocatalysts, which are expressed at high levels with retention of activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Cornell University, Robert F. Smith School of Chemical and Biomolecular Engineering, Ithaca, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
2 Cornell University, Cornell Institute of Biotechnology, Ithaca, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
3 Glycobia, Inc., Ithaca, USA (GRID:grid.420438.9)
4 University of Georgia, Complex Carbohydrate Research Center, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X)
5 Northwestern University, Department of Chemical and Biological Engineering, Evanston, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
6 Brigham Young University, Department of Physiology & Developmental Biology, Provo, USA (GRID:grid.253294.b) (ISNI:0000 0004 1936 9115)
7 Cornell University, Robert F. Smith School of Chemical and Biomolecular Engineering, Ithaca, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Cornell University, Cornell Institute of Biotechnology, Ithaca, USA (GRID:grid.5386.8) (ISNI:000000041936877X)